EP1831251A1 - Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide - Google Patents

Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide

Info

Publication number
EP1831251A1
EP1831251A1 EP05821738A EP05821738A EP1831251A1 EP 1831251 A1 EP1831251 A1 EP 1831251A1 EP 05821738 A EP05821738 A EP 05821738A EP 05821738 A EP05821738 A EP 05821738A EP 1831251 A1 EP1831251 A1 EP 1831251A1
Authority
EP
European Patent Office
Prior art keywords
peptide
amyloid
acid
peptides
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05821738A
Other languages
English (en)
French (fr)
Inventor
Rinaldo Zurbriggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pevion Biotech Ltd
Original Assignee
Pevion Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pevion Biotech Ltd filed Critical Pevion Biotech Ltd
Priority to EP05821738A priority Critical patent/EP1831251A1/de
Publication of EP1831251A1 publication Critical patent/EP1831251A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP05821738A 2004-12-30 2005-12-21 Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide Withdrawn EP1831251A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05821738A EP1831251A1 (de) 2004-12-30 2005-12-21 Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04031023A EP1676859A1 (de) 2004-12-30 2004-12-30 Immunogene Zusammensetzungen aus zyklischen Peptiden abgegleitet vom beta-Amyloid Peptid
PCT/EP2005/013823 WO2006069718A1 (en) 2004-12-30 2005-12-21 Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
EP05821738A EP1831251A1 (de) 2004-12-30 2005-12-21 Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide

Publications (1)

Publication Number Publication Date
EP1831251A1 true EP1831251A1 (de) 2007-09-12

Family

ID=34928060

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04031023A Withdrawn EP1676859A1 (de) 2004-12-30 2004-12-30 Immunogene Zusammensetzungen aus zyklischen Peptiden abgegleitet vom beta-Amyloid Peptid
EP05821738A Withdrawn EP1831251A1 (de) 2004-12-30 2005-12-21 Immunogene zusammensetzungen aus zyklischen peptide abgegleitet vom beta-amyloid peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04031023A Withdrawn EP1676859A1 (de) 2004-12-30 2004-12-30 Immunogene Zusammensetzungen aus zyklischen Peptiden abgegleitet vom beta-Amyloid Peptid

Country Status (7)

Country Link
US (1) US20080107649A1 (de)
EP (2) EP1676859A1 (de)
AU (1) AU2005321495A1 (de)
CA (1) CA2592690A1 (de)
EA (1) EA010586B1 (de)
WO (1) WO2006069718A1 (de)
ZA (1) ZA200705179B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
CN101330923B (zh) * 2005-12-12 2015-01-07 Ac免疫有限公司 治疗性疫苗
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP2046822B1 (de) * 2006-07-12 2012-01-04 Agency for Science, Technology and Research Molekulare sonde für sphingolipide
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
AU2008287530A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
BRPI0817682A2 (pt) 2007-10-16 2015-04-07 Peptimmune Inc Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos
EP2106802A1 (de) * 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modifizierte Peptide als synthetische Impfungen bei Amyloid-bedingten Krankheiten
CA2759118A1 (en) 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
MX2011000975A (es) * 2008-07-25 2011-05-25 Abbott Lab Analogos de peptido b amiloide, oligomeros de los mismos, procedimientos para preparar y composiciones que comprenden dichos analogos u oligomeros, y sus usos.
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US20120016598A1 (en) * 2010-05-21 2012-01-19 Bruker Daltonik Gmbh Normalization of mass spectra acquired by mass spectrometric imaging
US9364449B2 (en) 2010-06-09 2016-06-14 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
EP3374379A4 (de) * 2015-11-09 2019-05-15 The University Of British Columbia N-terminale epitope in amyloid-beta und konformationsselektive antikörper dagegen
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
IL296322A (en) 2020-03-10 2022-11-01 Lifearc Cyclic peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006069718A1 *

Also Published As

Publication number Publication date
ZA200705179B (en) 2008-08-27
CA2592690A1 (en) 2006-07-06
US20080107649A1 (en) 2008-05-08
EA200701305A1 (ru) 2007-12-28
WO2006069718A1 (en) 2006-07-06
EA010586B1 (ru) 2008-10-30
AU2005321495A1 (en) 2006-07-06
EP1676859A1 (de) 2006-07-05
WO2006069718A9 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
US20080107649A1 (en) Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
EP2380588B1 (de) Therapeutischer Impfstoff
US9975946B2 (en) Antibodies obtainable using supramolecular constructs
EP2408807B1 (de) Verfahren zur therapeutischen anwendung
Zurbriggen et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease
KR20200143422A (ko) 항-aveta 치료적 백신
AU2004240707A1 (en) Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's Disease
WO2003074558A2 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
MX2008007149A (en) Therapeutic vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20071030

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100608